Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Schott Pharma AG KGaA's 3-Year RORE % for the quarter that ended in Mar. 2026 was 5.24%.
The industry rank for Schott Pharma AG KGaA's 3-Year RORE % or its related term are showing as below:
SHTPY's 3-Year RORE % is ranked better than 56.91% of 782
companies
in the Medical Devices & Instruments industry
Industry Median: -4.31
vs SHTPY: 5.24
Schott Pharma AG KGaA (OTCPK:SHTPY) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Schott Pharma AG KGaA 3-Year RORE % Related Terms
Schott Pharma AG KGaA 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTPY vs ISRG, BDX, MDLN: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Schott Pharma AG KGaA (SHTPY) has a 3-Year RORE % of 5.24 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Schott Pharma AG KGaA and its competitors. According to the industry distribution chart, Schott Pharma AG KGaA ranks #337 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 43.1%.
Is Schott Pharma AG KGaA's 3-Year RORE % too high?
Schott Pharma AG KGaA's current 3-Year RORE % is 5.24. Based on the distribution chart, Schott Pharma AG KGaA ranks #337 out of 782 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's 3-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #337 out of 782 companies for 3-Year RORE %. This puts Schott Pharma AG KGaA in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Schott Pharma AG KGaA and its competitors. Schott Pharma AG KGaA's current 3-Year RORE % is 5.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current 3-Year RORE % of 5.24. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current 3-Year RORE % is 5.24. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current 3-Year RORE % is 5.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.
Key valuation signals for SHTPY:
3-Year RORE %: 5.24
GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score
Get the complete analysis for SHTPY
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
